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Abstract
A stable latent reservoir for HIV-1 in resting CD4+ T-cells precludes cure1–3. Curative strategies 
targeting the reservoir are being tested4,5 and require accurate, scalable reservoir assays. The 
reservoir was defined with quantitative viral outgrowth assays (QVOAs) for cells releasing 
infectious virus following one round of T-cell activation1. However, QVOAs and newer assays for 
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cells producing viral RNA after activation6 may underestimate reservoir size because one round of 
activation does not induce all proviruses7. Many studies rely on simple PCR-based assays to detect 
proviral DNA regardless of transcriptional status, but the clinical relevance of these assays is 
unclear, as the vast majority proviruses are defective7–9. We describe a novel approach that 
separately quantifies intact and defective proviruses and show that the dynamics of cells carrying 
intact and defective proviruses are different in vitro and in vivo, a finding with implications for 
targeting the intact proviruses that are a barrier to cure.
Evaluation of cure strategies requires assays that detect infected cells and distinguish intact 
proviruses from the vast excess of defective proviruses. We define intact proviruses as those 
lacking overt fatal defects such as large deletions and hypermutation7,8, recognizing that 
some proviruses so defined may have minor defects affecting fitness. We analyzed 431 near 
full genome HIV-1 sequences obtained by single genome analysis8,9 from 28 HIV-1-infected 
adults. The near full genome sequencing (nFGS) methods used identify defects throughout 
the genome except the 5′ LTR. Consistent with previous reports8,9, only 2.4% of proviruses 
were intact (Fig. 1a). The remaining 97.6% had fatal defects including deletions, 
encompassing on average 49.6% of the genome, and/or G→A hypermutation, which altered 
start codons and/or introduced stop codons in most ORFs8. Most defective proviruses had 
defects affecting most HIV-1 genes (Fig. 1b, Table S1). 97% of defective proviruses had 
defects affecting the transcriptional activator Tat (Fig. 1b, Table S1) and might not be 
efficiently transcribed after latency reversal. Thus, cure interventions dependent on viral 
gene expression4,5 may affect cells with intact and defective proviruses differently. Hence 
separate quantitation is essential.
Standard PCR assays use short subgenomic amplicons in conserved regions (Fig. 1c,d) and 
do not distinguish intact and defective proviruses. Deletions occur throughout the genome 
(Fig. 1e), affecting not only the fraction of proviruses detected (Fig. 1f) but also the fraction 
of detected proviruses that are intact (Fig. 1g). For most standard PCR assays, <10% of 
detected sequences are intact (Fig. 1g). Thus efficacy of a cure intervention causing a 
selective one log reduction in intact proviruses may be inapparent (Fig. 1h).
Interrogating individual proviruses simultaneously at multiple positions could differentiate 
intact from defective proviruses. Analysis of nFGS data revealed that strategically placed 
amplicons in the packaging signal (Ψ) and env regions could jointly identify >90% of 
deleted proviruses as defective (Fig. 2a). Hypermutated proviruses must also be identified 
(Fig. 1a). 73% of these have mutations in the GG→AG context (Extended Data Fig. 1a). 
Most also have GA→AA mutations. Only 27% of hypermutated proviruses had only 
GA→AA mutations, and most of these also had deletions (Extended Data Fig. 1a). 
Therefore, we focused on GG→AG hypermutation. We identified a conserved region in the 
Rev-response element (RRE) with adjacent consensus sites (TGGG) for responsible enzyme, 
APOBEC3G10 (Fig. 2b-e). Of sequences with GG→AG hypermutation, 97% had one or 
more mutations in this region (Fig. 2c,e), with 13 distinct patterns (Fig. 2f). Using mutant 
plasmids carrying each pattern, we developed allelic discrimination probes (Extended Data 
Fig.1b) that correctly identify 95% of hypermutated sequences as defective (Fig. 2f).
Bruner et al. Page 2
Nature. Author manuscript; available in PMC 2019 July 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
These analyses allowed design of a droplet digital PCR (ddPCR) that distinguishes most 
deleted and/or hypermutated proviruses from intact proviruses using two amplicons and 
hypermutation discrimination probes (Fig. 3a,b). Genomic DNA (gDNA) is isolated using an 
optimized method to minimize DNA shearing between targeted regions (see below) and 
partitioned into nanodroplets such that individual droplets rarely contain >1 provirus (P = 
0.00416). Proviruses within droplets are analyzed simultaneously at the Ψ and env regions 
via multiplex PCR, with the env PCR also discriminating hypermutated proviruses. Intact 
proviruses give amplification at both regions (Fig. 3a,b). Intact proviruses/106 cells are 
calculated using separate amplification of a cellular gene (RPP30) after correction for DNA 
shearing.
The ability of this intact proviral DNA assay (IPDA) to distinguish intact and defective 
proviruses was verified using plasmid controls representing proviruses with different defects. 
These templates gave positive droplets in the expected quadrants: Q1 for 3′ deletion and/or 
hypermutation and Q4 for 5′ deletion (Extended Data Fig. 2). Cultured clonal populations 
of infected patient cells also give single quadrant patterns (see below). In contrast, 
uncultured polyclonal patient CD4+ T-cell populations gave droplets in all four quadrants, 
allowing separate quantitation of intact and defective proviruses (Fig. 3c).
Validation of the IPDA is described in Extended Data Figs. 3 and 4. DNA shearing is 
essential for droplet formation but artificially reduces double positive (Q2) droplets while 
increasing Q1 and Q4 droplets. To control for shearing, two regions of a cellular gene 
(RPP30) with the same spacing as the Ψ and env amplicons are amplified in a separate 
multiplex ddPCR on each sample. This gives a DNA shearing index (DSI) to correct raw 
HIV-1 ddPCR results (see Methods). To validate this approach, DNA from JLat cells11, 
which contain a single provirus, was subjected to different amounts of shearing and analyzed 
by ddPCR for HIV-1 and RPP30. At all levels of shearing, DSI was similar for HIV-1 and 
RPP30. Thus RPP30 shearing can be used to correct for HIV-1 shearing (Fig. 3d). At all 
levels of shearing, corrected results were close to the expected values of 1 copy/cell for 
HIV-1 (Fig. 3e) and 4 copies/cell for RPP30 (JLat cells are tetraploid for RPP30). With 
correction for shearing, the IPDA gives highly accurate discrimination between molecularly 
defined standards representing intact and defective proviruses (Extended Data Fig. 5). In 
acute in vitro infections, high molecular weight DNA from productively infected CD4+ T-
cells showed a substantial fraction of intact proviruses as assessed by IPDA and confirmed 
by nFGS (Extended Data Fig. 6). Thus, the assay can reliably quantitate intact proviruses in 
most DNA samples after correction for shearing.
Using samples of only 5×106 cells, we measured intact and defective proviruses in 62 
infected individuals who had suppression of viremia on antiretroviral therapy (ART) (n=57) 
or “elite” control of HIV-1 without ART (n=5) (Table S3). The mean DSI was 0.32±0.07 
(Extended Data Fig. 7), well within the range for which accurate correction is possible. 
Intact proviruses were rare (~100/106 resting CD4+ T cells) and greatly outnumbered by 
defective proviruses (Fig. 3f). These results provide the first demonstration with a method 
not requiring long distance PCR that the proviral landscape is dominated by defective 
proviruses. We found strong correlations between IPDA and QVOA measurements on the 
same samples (r=0.48, p=0.003, n=35, Fig. 3g) even though the fraction of intact proviruses 
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induced by a single round of T-cell activation in the QVOA is small and variable between 
individuals (Fig. 3h).
Using nFGS data, we compared the IPDA with the widely used gag PCR with respect to 
desired assay characteristics. IPDA detects a larger fraction of proviruses (Fig. 3i) and 
separately enumerates intact and two class of defective proviruses. More importantly, the 
IPDA excludes 97% of proviruses with defects detectable by nFGS (Fig. 3i). The fraction of 
defective proviruses excluded by standard PCR assays is much lower and almost zero for 
Alu-PCR assays. It is only 30% for gag PCR. Most proviruses (~70%) classified as intact by 
IPDA lack defects detectable by nFGS. In contrast, this value is <10% for gag PCR (Fig. 3i). 
Thus the IPDA provides a scalable alternative that is much more selective for intact 
proviruses. Most defects missed by IPDA are small deletions not overlapping IPDA 
amplicons. In addition, although nFGS data used to design the assay covers 97.6% of the 
non-redundant HIV-1 sequence, small deletions in the remaining portion of the genome may 
be present in some proviruses. The assay was designed for use in treated patients and does 
not distinguish integrated proviruses from unintegrated linear or circular forms. These are 
rare in patients on long term ART8. Additional sequence data and improved ddPCR 
technology may allow even greater selectivity for intact proviruses. Importantly, selective 
intervention-induced reductions in intact proviruses would be apparent with the current 
IPDA but not with standard assays (Fig. 3i).
The latent reservoir measured by QVOA undergoes slow decay (t1/2=44 months)12,13. Intact 
proviruses measured by IPDA show similar decay (Fig. 4a,b). For most patients, intact 
proviruses declined with a t1/2 of ~44 months. Some patients showed even slower decay 
(t1/2=100–300 months), and for 3/14 patients, there was no decay (Fig. 4b,c). Thus the IPDA 
can measure changes consistent with known reservoir dynamics and possibly define 
subpopulations with slower decay.
The dynamics of defective proviruses in the same patients showed greater variability, with 
increases over time in some patients (Fig. 4a,c, Extended Data Fig. 8). While the mean 
decay slopes did not differ, the standard deviations of decay slopes were much greater for 
defective proviruses (Extended Data Fig. 9), complicating interpretation of assays dominated 
by defective forms. Increases in infected cell frequency can reflect the proliferation of 
infected cells14–19. Although the IPDA cannot demonstrate the presence of expanded clones, 
it can detect increases in infected cell frequency due to clonal expansion. We asked whether 
the differential dynamics of cells with intact and defective proviruses could be due to uneven 
distribution in subsets of memory CD4+ T-cells20 with different proliferative potential. Intact 
and defective proviruses were found in expected ratios in central, transitional, and effector 
memory subsets (Fig. 4d). We then asked whether intact and defective proviruses imposed 
different constraints on proliferation. We used the IPDA to track individual infected cells 
from treated patients following in vitro stimulation with anti-CD3/28 (Fig. 4e). 
Microcultures seeded with ~1 infected cell/well were subjected to 4 rounds of stimulation in 
the presence of antiretroviral drugs. Analysis of >1700 microcultures showed that positive 
droplets were detected in only one of three possible quadrants for most positive wells, as 
expected for cultures initiated with a single infected cell and cultured with antiretroviral 
drugs (Fig. 4e). Most (97.6%) proviruses were defective (Fig. 4f). Importantly, the IPDA 
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also counts proviruses in each well allowing direct quantitation of infected cell proliferation. 
Some cells carrying defective proviruses showed enormous clonal expansion (1000 fold) 
while cells with intact proviruses were rarely detected and showed little proliferation (Fig. 
4f). Despite fewer wells with intact provirues, differences in the mean number of intact and 
defective proviruses per well remained highly significant (P=0.0029 to P<0.0001 by 
unpaired t test with Welch’s correction for intact proviruses vs proviruses with 
hypermutation and/or 3’ deletions). These differences are minimal estimates because the 
fraction of positive microcultures with intact proviruses was lower than expected based on 
IPDA analysis of the starting population (3.3% vs 7.5%), indicating that some cells with 
intact proviruses die. These results demonstrate a proliferative defect in response to 
repetitive in vitro TCR stimulation for cells carrying intact proviruses and show that the 
IPDA can be a useful initial high-throughput screening tool for mechanistic studies with the 
caveat that not all Q2 droplets represent intact proviruses (Fig. 3i).
Analysis of proviral integration sites14,15,21 of expanded clones demonstrated that the 
cultures were clonal and that integration into genes with cancer association was not required 
for proliferation (Fig. 4f, Table S4). Rather proliferative potential is related to proviral 
defects. nFGS confirmed the clonal nature of the proviruses in each well and demonstrated 
directly that the IPDA correctly identifies the presence and nature of defects in proviruses 
(Fig. 4g). Of 12 clonally expanded defective proviruses sequenced, 9 were defective in all 
HIV-1 ORFs, and none were fully competent for expression of Tat or of Vif, Vpr, Vpu, Env, 
or Nef. Low or absent expression of these genes would allow stimulated cells to escape viral 
cytopathic effects that could limit proliferation22,23.
The failure of cells carrying intact proviruses to expand following repetitive in vitro TCR 
stimulation provides insights into the mechanisms driving in vivo clonal expansion16–18,24 
and into cure strategies involving T-cell activation. The reservoir of intact proviruses 
undergoes slow decay in vivo, as shown here and previously12,13. Thus observed clonal 
expansions14–19 must be more than offset by the death of infected cells. Strong TCR 
stimulation may induce viral gene expression and cell death or impaired proliferation as 
shown in our in vitro experiments. Clonal expansion in vivo may be driven by stimuli 
including homeostatic cytokines that allow proliferation without virus production19,20.
Our results show that the small subset of proviruses with the potential to cause viral rebound 
show different dynamics than the vast excess of defective proviruses captured in standard 
PCR assays, emphasizing the importance of direct measurement of intact proviruses. The 
availability of a scalable assay for intact proviruses should accelerate cure research.
Methods
Study participants.
Characteristics of study participants are given in Table S3. The Johns Hopkins Institutional 
Review Board and the UCSF Committee on Human Research approved this study. All 
participants provided written consent prior to enrollment. Except where indicated, 
participants were HIV-1 infected adults on suppressive ART with undetectable plasma 
HIV-1 RNA levels (< 50 copies per mL) for >6 months. Chronic phase (CP)-treated subjects 
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are defined as subjects starting ART >180 days from the estimated date of infection. Acute 
phase (AP)-treated subjects started ART < 100 days after the estimated date of infection. For 
longitudinal analysis, additional peripheral blood mononuclear cell (PBMC) samples were 
obtained from 10 HIV-1-infected men followed in the Baltimore-Washington DC center of 
the Multicenter AIDS Cohort Study (MACS)27 who had undetectable plasma HIV RNA 
(<20 copies/ml by Roche Taqman assay) at all semiannual study visits for 5 years or more, 
with no blips or missed visits. PBMC cryopreserved at visits at least 5 years apart, and 
viably stored as per MACS protocols, were studied. Characteristics of these 10 men are 
given in Table S3 (CP31-CP49).
CD4+ T-cell isolation.
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation using 
Ficoll-Paque PLUS (GE Healthcare Life Sciences; Marlborough, MA) per manufacturer’s 
instructions. Untouched total CD4+ T-cells were then enriched from PBMC using negative 
immunomagnetic selection via the EasySep Human CD4+ T-Cell Enrichment Kit (StemCell 
Technologies; Vancouver, BC). In some experiments, resting CD4+ T-cells (CD4+, CD69−, 
CD25− and HLA-DR−) were isolated using a second negative selection step (CD25-Biotin; 
Anti-Biotin MicroBeads; CD69 MicroBead Kit II; Anti–HLA-DR MicroBeads, all from 
Miltenyi Biotec). Resting CD4+ T-cell purity was consistently >95% as assessed using flow 
cytometry.
Bioinformatic analysis.
We constructed an alignment of 431 published8,9 full length proviral sequences obtained 
from 28 HIV-1-infected adults by single genome analysis. Of these individuals, 19 started 
suppressive ART during chronic infection while 9 started suppressive ART during acute 
infection. 24 had prolonged suppression of viremia (>6 months) when studied, and 5 were 
viremic when studied (one individual was studied at two time points, before and after ART). 
Clinical characteristics of these individuals are given in the relevant publications8,9. The 
proportion of different types of defects in HIV-1 proviruses varies with the stage of disease 
at which ART is started and the level of viremia8. For most analyses, we used sequences 
from patients who initiated ART during chronic infection and who had sustained 
suppression of viremia to below 50 copies HIV-1 RNA/ml of plasma for >6 months. These 
sequences (n=211) are thus representative of the most common group of infected individuals 
who would be eligible for cure interventions. The proviral landscape in patients starting 
ART during acute infection is also dominated by defective sequences, with a higher fraction 
showing hypemutation8. In the analysis of deletions, common length polymorphisms were 
not included. Terminal deletions preclude integration and are not seen. Internal deletions in 
the 5’ LTR are not evaluable because the nFGS methods do not capture this region. 
Hypermutation occurred with or without deletions. For analyses of specific type of defects, 
we used all sequences in the database with that defect. For examples, for analysis of 
hypermutation, we used all database sequences with hypermutation (n=100) and additional 
hypermutated sequences obtained by single genome env sequencing. Hypermutation in the 
GG or GA context was confirmed using the Hypermut algorithm28. Positions of primers for 
ddPCR analysis were evaluated using a sliding window analysis of two hypothetical 100 bp 
amplicons, scoring for lack of significant overlap (>5%) with mapped deletions in the 
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database sequences with deletions. Optimal discrimination between intact and deleted 
sequences is obtained with a 5′ amplicon in the Ψ region and a 3′ amplicon in env. Ψ is the 
site of frequent small deletions and is included in larger 5′ deletions. Sequence conservation 
was evaluated using separate alignments of US clade B sequences from the Los Alamos HIV 
sequence database (https://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html).
Intact proviral DNA assay (IPDA).
A variety of experimental conditions were used in the development of the IPDA. The 
following is an optimized recommended procedure. In general, the IPDA is performed on 
DNA from 5×106 CD4+ T-cells. Genomic DNA is extracted using the QIAamp DNA Mini 
Kit (Qiagen; Hilden, Germany) with precautions to avoid excess DNA fragmentation. DNA 
concentrations are determined using the Qubit3.0 and Qubit dsDNA BR Assay Kit 
(ThermoFisher Scientific; Waltham, MA). Quantification of intact, 5’ deleted, and 3’ deleted 
and/or hypermutated proviruses is carried out using primer/probe combinations optimized 
for subtype B HIV-1 (Table S5). A qualified research use only (RUO) version of the primer/
probe mix is available from Accelevir Diagnostics, Baltimore, MD (HIV-1 Proviral 
Discrimination 20x primer/probe mix). The primer/probe mix is comprised of 
oligonucleotides for two independent hydrolysis probe reactions which interrogate 
conserved regions of the HIV-1 genome to discriminate intact from defective proviruses. 
HIV-1 Reaction A targets the packaging signal (Ψ) which is a frequent site of small deletion 
and is included in many large deletions in the proviral genome. The Ψ amplicon is 
positioned at HXB2 coordinates 692–797. This reaction utilizes forward and reverse 
primers, as well as a 5’ 6-FAM labelled hydrolysis probe. Successful amplification of HIV-1 
Reaction A produces a FAM fluorescence in droplets containing Ψ, detectable in channel 1 
of the droplet reader. HIV-1 Reaction B targets the Rev-Response Element (RRE) of the 
proviral genome, with the amplicon positioned at HXB2 coordinates 7736–7851. This 
reaction utilizes forward and reverse primers, as well as two hydrolysis probes: a 5’ VIC 
labelled probe specific for wild-type proviral sequences and a 5’ unlabeled probe specific for 
APOBEC-3G hypermutated proviral sequences (Fig. S2). Successful amplification of HIV-1 
Reaction B produces a VIC fluorescence in droplets containing a wild-type form of RRE, 
detectable in channel 2 of the droplet reader, while droplets containing a hypermutated form 
of RRE are not fluorescent.
Droplets containing HIV-1 proviruses are scored as follows. Droplets positive for FAM 
fluorescence only, which arises from Ψ amplification, score as containing 3′ defective 
proviruses, with the defect attributable to either APOBEC-3G-mediated hypermutation or 3′ 
deletion. Droplets positive for VIC fluorescence only, which arises from wild-type RRE 
amplification, score as containing 5′ defective proviruses, with the defect attributable to 5′ 
deletion. Droplets positive for both FAM and VIC fluorescence score as containing intact 
proviruses (Fig. 3a.b). Double negative droplets contain no proviruses or rare proviruses 
(~3.8%) with defects affecting both amplicons.
An important aspect of the quantitation of intact proviruses is correction for DNA shearing 
between amplicons which artificially reduces Q2 droplets while increasing Q1 and Q4 
droplets (Fig. 3b). This can be done accurately through ddPCR analysis of a host gene, 
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which also provides a measure of input cell number. In principle, any host gene can be used, 
with two ddPCR amplicons spaced at the same distance as the HIV-1 amplicons described 
above. As demonstrated in Fig. 3d and 3e, this approach allows for accurate correction for 
DNA shearing. Simultaneous quantification of DNA shearing and input human genome 
equivalents is performed using another aliquot of the same DNA sample. For the studies 
described here, oligonucleotides for two independent hydrolysis probe reactions which 
interrogate the human RPP30 gene (Chr.10: 90,880,081 on GRCh38) were used. A qualified 
RUO RPP30 primer/probe mix is available from Accelevir Diagnostics, Baltimore, MD 
(DNA Shearing + Copy Reference 20x primer/probe mix). In this primer/mix, the total 
distance between duplex reactions and individual amplicon sizes are equivalent to those of 
the HIV-1 proviral discrimination reactions described above. Optimal reaction melting 
temperatures are equivalent for all reactions. Comprehensive oligonucleotide analysis 
predicted no potential off-target nucleotide binding or amplification (BLASTn) and no self-
dimerization, hetero-dimerization, or primer hairpin formation. RPP30 Reaction A employs 
a 5’ 6-FAM labelled hydrolysis probe, and RPP30 Reaction B employs a 5’ HEX labelled 
hydrolysis probe. Droplets positive for both 6-FAM and HEX fluorescence score as 
containing an unsheared RPP30 gene fragment, while droplets positive for only a single 
fluorescence score as containing part of a sheared RPP30 gene fragment. The ratio of dual 
fluorescent to single fluorescent droplets is used to calculate a DNA Shearing Index (DSI), 
and this index is applied to both genome copy number input reactions and HIV-1 proviral 
discrimination reactions to correct for experimentally observed DNA shearing.
Droplet digital PCR was performed on the Bio-Rad QX200 AutoDG Digital Droplet PCR 
system using the appropriate manufacturer supplied consumables and the ddPCR Supermix 
for probes (no dUTPS) (Bio-Rad Laboratories; Hercules, CA). For HIV-1 proviral 
discrimination reactions, 700 ng of genomic DNA was analyzed in each reaction well. For 
DNA shearing and copy number reference reactions, 7 ng of genomic DNA was analyzed in 
each reaction well. Multiple replicate wells were performed for each reaction type to ensure 
consistent quantitation, and replicate wells were merged during analysis to increase IPDA 
dynamic range. The thermal cycling program used for all reactions, with a 2°C ramp rate, is 
given in Table S6. In general, parallel processing and analysis of uninfected donor CD4+ T-
cells was performed for each IPDA run as a negative control while qualified JLat6.3 
genomic DNA was analyzed in each IPDA run as a positive control. After correction for 
DNA shearing, results are expressed as proviral copies per 106 CD4+ T-cells.
Cell Lines.
The J-Lat Full Length Clone (clone #6.3) from Dr. Eric Verdin was obtained through the 
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH.
Quantitative viral outgrowth assay (QVOA).
The QVOAs were performed as previously described1,29. MOLT-4/CCR5 cells30 were added 
on Day 2 of the culture and the culture supernatants were examined for the p24 viral capsid 
protein by ELISA (PerkinElmer) after 14 and 21 days. Results were expressed as infectious 
units per million cells (IUPM) CD4+ T-cells calculated using maximal likelihood as 
described by Rosenbloom et al (IUPMStats31).
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T-cell subset analysis.
Resting CD4+ T cells from HIV-1-infected donors on suppressive ART were isolated as 
described above. To sort resting memory subsets, we incubated cells with FcgR block (BD 
Pharmingen) for 10 minutes before staining with a FITC-labeled antibody to CD3 
(Biolegend; Clone HIT3a), phycoerythrin (PE)-Cy7-labeled antibody to CD4 (Biolegend; 
Clone RPA-T4), allophycocyanin (APC)-labeled antibody to CD45RO (Biolegend; Clone 
UCHL1), BV421-labeled antibody to CD27 (Biolegend; Clone O323) and PE-labeled 
antibody to CCR7 (Biolegend; Clone G043H7). Dead cells were excluded using propidium 
iodide. PE Mouse IgG2aκ, BV421 Mouse IgG1κ, and APC IgG2aκ isotype antibodies were 
used in fluorescence-minus-one controls to set sorting gates. Memory cells were 
distinguished from naive cells by the presence or absence of CD45RO staining, respectively. 
Central memory cells were distinguished from effector and transitional memory subsets by 
the presence of CCR7 as described by Sallusto et al32. CCR7- cells were subdivided into 
effector memory (Tem) (CD45RO+CCR7-) or transitional memory (Ttm) (CD45RO+CCR7-
CD27+) as described by Chomont et al20. Central, effector, and transitional resting memory 
subsets were sorted using a Beckman Coulter MoFlo XDT Cell sorter.
Clonal microcultures.
Purified resting CD4+ T-cells from HIV-1-infected donors on suppressive ART were 
analyzed for proviral DNA copies using gag qPCR as previously described33. The resulting 
values were corrected for gag− proviruses, and cells were plated at approximately one 
infected cell per well (2000–4000 total resting CD4+ T-cells) in 96-well plates. The cells 
were then stimulated with anti-CD3/CD28 Dynabeads (25 μl per million cells; Thermo 
Fisher Scientific) in RPMI containing 10% fetal bovine serum and 100 U/mL IL-2 
(Novartis) for 7 days in the presence of tenofovir disoproxil fumarate (10 μM) and 
emtricitabine (10 μM). Half of the media in each well was removed and replaced with fresh 
media, anti-CD3/CD28 Dynabeads and antiretroviral drugs weekly for 2–3 weeks. DNA 
isolation was performed on cells from each well using a Quick-DNA 96 Kit (Zymo Research 
Corporation). 1/4th of the extracted DNA was analyzed by the IPDA to determine the type 
of provirus and proviral copy number in each well. The remaining DNA was used for 
integration site analysis and full genome sequencing.
Integration site analysis.
Integration site analysis was performed using previously described linker ligation 
method26,34,35. Sites for which both the 5ʹ and 3ʹ junctions were captured are shown. 
Cancer associations were determined as previously described35.
Full genome sequencing.
Full genome sequencing was performed at the single molecule level as previously 
described8.
Data Availability.
The IPDA was developed through an analysis of published near full genome HIV-1 
sequences (references 8 and 9, Genbank accession numbers KX505390-KX505744 and 
KU677989-KU678196, respectively).
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Extended Data
Extended Data Fig. 1. Analysis of hypermutation.
(a) The majority of hypermutated proviruses show both GG→AG and GA→AA patterns of 
hypermutation. Based on hypermutated full-genome sequences in the database (n=100). 
Sequences were analyzed for GG→AG and GA→AA patterns using the using the all 
available sequence for each clone and the Los Alamos hypermut algorithm17. (b) 
Hypermutation discrimination using two probes in the RRE of the env gene. The intact 
probe hybridizes with a region containing two adjacent APOBEC3G consensus sites (red 
underline) in intact proviruses. It is labeled with a fluorophore (VIC) and a quencher (Q). 
Also present in the reaction is a hypermutated probe which lacks the fluorophore and which 
does not bind (arrow) to intact proviral sequences due to G→A mutations at both 
APOBEC3G consensus sites. Dashed boxes indicate the nucleotide positions of sequence 
differences between the intact and hypermutated probes. The hypermutated probe 
preferentially binds to the same region in hypermutated proviruses. It lacks a fluorophore 
and prevents binding of the fluorophore-labeled intact probe (arrow). Therefore, no 
fluorescent signal is generated for 95% of hypermutated proviruses (Fig. 2f).
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Extended Data Fig. 2. Plasmid controls show the specificity of the IPDA.
(a) Maps of proviral plasmid control templates. Plasmids E44E11, 39G2, and 4F11 have 
deletions in the indicated regions (white). Plasmid 2G10 is a heavily hypermutated patient-
derived sequence with G→A mutations in probe binding region of the env amplicon 
(enlarged region). Plasmid 19B3 has GA point mutations in this region. These G→A 
mutations (red) occur at two APOBEC3G consensus sites (TGGG, underlined) in this 
region. These plasmids have been previously described12,34. (b-e) IPDA on plasmids 
representing the indicated defective proviruses showing positive droplets only in the 
expected quadrants.
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Extended Data Fig. 3. IPDA accuracy, reproducibility, and limit of quantification.
(a) Correlation between expected and IPDA-measured frequencies of intact proviruses per 
106 cells. Genomic DNA from uninfected donor CD4+ T-cells was spiked with JLat6.3 DNA 
cell equivalents and subjected to a serial four-fold dilution. This material was then analyzed 
by the IPDA, and the IPDA-measured frequencies of intact proviruses per million cells were 
compared to the expected frequencies (998, 249.5, 62.4, 15.6, and 3.9 intact proviruses per 
106 CD4+ T-cells). This experiment was performed independently three times. The 
agreement between the expected and IPDA-measured frequencies of intact proviruses was 
determined using Pearson correlation. (b) Reproducibility of the IPDA across independent 
assay runs. Reproducibility was assessed by determining the coefficient of variation (CV) 
across three independent assay measurements of genomic DNA from uninfected donor 
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CD4+ T-cells spiked with JLat6.3 cell equivalents and subject to serial four-fold dilution, as 
described in (a).
Extended Data Fig. 4. IPDA reproducibility.
Frequencies of cells containing proviruses with 3′ deletions and/or hypermutation (a), 5′ 
deletions (b), or no defects (intact, c) in CD4+ T-cells from 28 treated patients. Each data 
point represents a replicate IPDA determination from a single sample from the indicated 
patient. The mean and SEM of the replicates are plotted. The variability between patients is 
much greater than the variation between replicates from a single patient. Technical replicates 
are shown to indicate low intrinsic variability of the IPDA.
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Extended Data Fig. 5. Plasmid controls confirm specificity of the IPDA.
(a) Map of the plasmid pNL4–3 carrying an intact HIV-1 provirus. Positions of the Ψ (blue) 
and env (green) IPDA amplicons and of a distinct set of plasmid shearing control (PSC, 
magenta boxes) amplicons are indicated. Spacing between PSC amplicons is equal to 
spacing between Ψ and env amplicons. Dotted lines indicate positions of deletions in 
plasmids carrying previously described12 defective proviruses E44E11 and 4F12 with 5′ 
and 3′ deletions, respectively. (b) IPDA analysis of the indicated Zra1-cut plasmids 
representing intact, 5′-deleted and 3′-deleted proviruses. (c) Summary of droplet counts for 
the experiment shown in (b). E44E11 and 4F12 give positive droplets only in quadrant 4 
(Q4) and Q1, respectively. For pNL4–3, >95% of droplets are in Q2, with the remainder 
attributable to shearing between the Ψ and env amplicons. (d) Analysis of shearing. For 
IPDA analysis of patient samples, shearing was measured using amplicons in the RPP30 
gene (Fig. 3a,d,e). For plasmid control experiments, shearing of ZraI-cut plasmids was 
analyzed using two sets of amplcons, the Ψ and env IPDA amplicons and the equally spaced 
PSC amplicons shown in (a). ddPCR analysis was done on fresh (D0) maxipreps of pNL4–3 
linearized with ZraI at a concentration mimicking patient samples. To assess the effects of 
higher levels of DNA fragmentation, IPDA analysis was also done on pNL4–3 DNA that had 
been incubated at 4oC for 5 days (D5), and on pNL4–3 DNA cut with both ZraI and EcoRI 
(2 cuts). The mean and range of duplicate determinations of the DNA shearing index (DSI) 
is shown for each set of amplicons. The DSI was the same for the IPDA and PSC amplicons 
at 3 different levels of shearing. The DSI was used to correct the IPDA droplet counts in (e). 
Negative values were set to 0. (e) Uncorrected and DSI-corrected IPDA analysis of the intact 
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proviral construct pNL4–3 at different levels of fragmentation. After correction, positive 
droplets were almost exclusively in Q2 even at higher levels of fragmentation.
Extended Data Fig. 6. Sequence analysis of Q2 proviruses.
(a) Sorting of productively infected CD4+ T-cells. Cell preparations with a high fraction of 
intact proviruses were obtained by infecting CD4+ T-lymphoblasts with a replication-
competent HIV-1 carrying GFP in the nef ORF (R7-GFP37). After 48 hours, GFP+ cells 
were collected by sorting. Genomic DNA was isolated, subjected to pulse field 
electrophoresis to remove unintegrated intermediates, and analyzed by IPDA. (b) IPDA 
analysis of high molecular weight DNA from sorted cells. Droplets in Q1 and Q4 largely 
reflect the shearing of intact proviruses (DSI = 0.46) during in DNA isolation and 
purification. (c) Frequency of intact proviruses in GFP− and GFP+ cells before and after 
correction for shearing. After correction for shearing, the frequency of intact proviruses in 
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sorted GFP+ cells is close to the expected value of 1. (d) Map of the HIV-1 genome in GFP-
expressing HIV-1 vector R7-GFP used in (a). GFP is inserted in the nef ORF. Positions of 
outer primers in the LTR and GFP used in single genome amplifications are indicated. (e) 
Sequence analysis of 9 independent single genomes. Arrows indicated positions of the Ψ 
and env IPDA amplicons. Orange lines indicate intact sequence without deletions or 
hypermutation and identical to R7-GFP except for single base mutations (black lines).
Extended Data Fig. 7. 
DNA shearing index (DSI) for patient samples (n=62). The DSI was determined by ddPCR 
using two amplions in a cellular gene (RPP30) spaced at exactly the same distance as the Ψ 
and env amplicons. It is the fraction of templates in which DNA shearing has occurred 
between the amplicons. Horizontal bars indicate media and interquartile range.
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Extended Data Fig. 8. 
In vivo decay rates of cells with intact and defective proviruses. The frequency of cells 
carrying intact proviruses, proviruses with 3′ deletion and/or hypermutation (3′ del/hyper), 
and proviruses with 5′ deletions (5′ del) was measured in resting CD4+ T-cells from 
patients on long term suppressive ART. Data are plotted in terms of decay rate assuming 
exponential decay. Half-life values for the same decay curves are sown in Fig. 4c. Negative 
decay rate indicates proliferation.
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Extended Data Fig. 9. 
Variability in decay slopes. Mean and standard deviation of the decay slopes for intact and 
defective proviruses in infected individuals on ART sampled longitudinally (n=14). Based 
on decay data in Fig. 4a.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
DNA PCR assays predominantly measure defective proviruses. (a) Proviruses persisting in 
CD4+ T-cells of individuals on suppressive ART as detected by nFGS8,9. Defects include 
internal stop codons, deletions not attributable to normal length polymorphisms, and 
APOBEC3G/F-mediated hypermutation (G→A). Most deletions were large except for those 
in the packaging signal (ψ)/major splice donor site. Based on 211 sequences from 
individuals initiating ART during chronic infection. (b) Fraction of defective proviruses with 
defects in the indicated genes or elements. Protein-coding genes were considered defective if 
any of the following are present: mutated start codon, internal stop codons, frameshifts, or 
insertions or deletions not representing common length polymorphisms. Splice site 
mutations further increased the fraction of defective sequences (lighter shaded portions of 
the bars for spliced genes). LTR sequences were considered defective if mutations in the 
NFκB sites and/or deletions were present. See Table S1 for details. (c) Positions of 
amplicons used in standard DNA and Alu-PCR assays. See Table S2 for coordinates and 
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references. Numbers distinguish distinct assays targeting the same region. Alu PCR assays 
also amplify host genomic sequence (arrows). (d) Conservation of sequence across the 
genome based on a US clade B sequences in the Los Alamos HIV Sequence Database 
(https://www.hiv.lanl.gov/). Plotted as % of sequences matching the consensus at each 
nucleotide. (e) Position of internal deletions across the HIV-1 genome. Plotted as % of total 
sequences from treated patients deleted at the indicated nucleotide. (f) Percent of all 
proviruses that are amplified by the indicated assay. Based on absence of overlap between 
deleted regions and the relevant amplicons. (g) Percent of the proviruses detected by the 
indicated assay that are intact. (h) Percent loss of assay signal following a selective 10-fold 
reduction in intact proviruses. For panels f-h, analysis is based 211 sequences from 19 
patients starting ART during chronic infection.
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Fig. 2. 
Distinguishing intact and defective HIV-1 proviruses. (a) Sliding window analysis of 
optimal amplicon positioning to detect deletions. Optimal discrimination between intact and 
deleted sequences is obtained with a 5′ amplicon in the Ψ region and a 3′ amplicon in env. 
Ψ is the site of frequent small deletions and is included in larger 5′ deletions. Based on 431 
independent near full genome sequences in the database including 258 that contain mapped 
deletions. Inclusion of an additional 474 sequences from treated patients did not change 
optimal positions. (b) Nucleotide conservation across the env gene based on US clade B 
sequences in the Los Alamos HIV Sequence Database, is plotted as percent of sequences 
matching the consensus sequence at each nucleotide. Shaded area is expanded in Fig. 2d. (c) 
GG→AG hypermutation across the env gene. The percent of hypermutated proviruses that 
contain one or more G→A mutations within a given APOBEC3G consensus site is plotted 
as a function of site position. Shaded area is expanded in Fig. 2e. (d) Sequence conservation 
of a region in the RRE containing two APOBEC3G consensus sites. Primer (arrows) and 
probe (box) positions for the env amplicon are shown. (e) Fraction of hypermutated 
proviruses with G→A mutations in the probe binding region (shaded). (f) Hypermutation 
patterns at the env probe binding site. The prevalence of 13 observed patterns is indicated in 
the bar graph on the left and in the “Percent” column. Mutations in the APOBEC3G 
consensus sites (underlined) are indicated in red. Based 93 independent hypermutated env 
sequences from 18 treated patients. Site directed mutagenesis was used to modify NL4–3 or 
a patient-derived proviral construct to generate plasmids containing each pattern. The 
“Amplified” column indicates that only 5% of hypermutated sequences were amplified by 
the probe combinations developed to identify intact sequences.
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Fig. 3. 
Intact proviral DNA assay (IPDA). (a) Assay schematic. Multiplex PCRs in droplets amplify 
Ψ and env regions. A separate multiplex PCR targets two regions of the human RPP30 gene 
spaced at the same distance as the Ψ and env amplicons to provide cell number quantitation 
and DNA shearing correction. See Methods for details. (b) Representative control ddPCR 
experiment using proviral constructs25 with a 5’ deletion (E44E11), a 3’ deletion (4F11), or 
no defects (NL4–3). 1,000 copies each were mixed with 500 ng of HIV-1 negative DNA to 
simulate a patient sample. Types of proviruses appearing in different quadrants are shown on 
the right. (c) Representative IPDA results from a patient CD4+ T-cell sample. Boxed areas 
are expanded to show individual positive droplets. (d) DNA shearing index (DSI, fraction of 
templates sheared between targeted regions) measured for RPP30 and HIV-1 on JLat DNA 
samples subjected to different levels of shearing (n=22). Compared using two tailed t-test for 
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paired non parametric values. (e) Use of DSI to correct raw ddPCR output for RPP30 and 
HIV. Mean and SD of copies/cell of RPP30 (blue) and HIV (orange) are shown before 
(circles) and after (triangles) correction for shearing. (f) IDPA results on CD4+ T-cells from 
infected individuals (n=62) with plasma HIV-1 RNA below the limit of detection. Bars 
indicate geometric mean ± SEM. See Table S3 for patient characteristics. Polymorphisms 
precluding amplification with either primer/probe set were not observed in this cohort and 
would require triage primer/probe sets incorporating rare polymorphisms. (g) Correlation 
between infected cell frequencies measured by QVOA and IPDA on the same samples of 
CD4+ T-cells from treated patients (n=36). IUPM, infectious units per million cells. (h) 
IPDA/QVOA ratios for samples from Fig. 3g. Horizintal bars indicate geometric mean and 
95% CI. (i) Bioinformatic comparison of standard gag PCR and IPDA with respect to % of 
proviruses amplified, % of defective proviruses excluded, % of amplified proviruses that are 
intact, and % loss in assay signal following a selective 10-fold reduction in intact proviruses. 
See legend to Fig. 1f-h for details.
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Fig. 4. 
IPDA reveals differential dynamics of intact and defective proviruses. (a) Decay of intact 
proviruses, proviruses with 3′ deletion and/or hypermutation (3′ del/hyper), and proviruses 
with 5′ deletions (5′ del) measured in resting CD4+ T cells from patients on long term 
ART. (b) Half-lives of cells carrying intact proviruses assuming exponential decay, from the 
data in (a). (c) Half-lives of populations of cells carrying intact and defective proviruses. 
Increasing frequencies are plotted as doubling times. (d) Distribution of intact and defective 
proviruses in memory CD4+ T-cell subsets. (e) System for examining the proliferation of 
infected cell clones. Total proviruses in resting CD4+ T-cells from patients on ART were 
measured using a standard gag PCR corrected for gag-deleted proviruses. Cells were diluted 
to ~1 infected cell/well (2000–4000 total resting CD4+ T cells/well) and stimulated 2–4 
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times with anti-CD3+anti-CD28 microbeads in the presence of IL-2 and antiretroviral drugs 
(see Methods) resulting in expansion to an average of 2×106 cells/well. DNA was isolated 
for IPDA and for integration site analysis and nFGS, performed as previously described8,26. 
(f) IPDA and integration site analysis of 1731 microcultures from 5 patients. Y-axis 
indicated number of proviruses in each positive culture. Colors indicate type of provirus 
detected. Bars indicate geometric mean of proviruses/culture for each provirus type. 
Statistical significance of differences was determined by Welch’s t-test. Integration sites for 
some clones with the highest proliferation are indicated in blue boxes. Pie charts indicate the 
fractions of integration sites in transcriptional units, intergenic regions, or with cancer 
associations for cultures with high (> 20 proviruses, top) or low (< 20 proviruses, bottom) 
proliferation. (g) nFGS results for cultures showing proliferation. Sequences were analyzed 
for defects affecting expression of each HIV-1 gene as described in Fig. 1b. Count indicates 
proviruses/culture as detected by IPDA.
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